Targeting the CaN/FoxO1/FABP4 Pathway to Prevent SERCA2 Dysfunction-Induced Atherosclerosis

Study Background and Research Question

Atherosclerosis remains a leading cause of cardiovascular morbidity, driven by complex interactions between lipid metabolism, chronic inflammation, and vascular cell dysfunction. A key process in atherogenesis is the formation of macrophage-derived foam cells, which accumulate modified lipids and contribute to plaque development and instability. Recent evidence suggests that intracellular calcium homeostasis, particularly via the sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2), is essential for maintaining normal vascular and metabolic function. However, the specific mechanistic links between SERCA2 dysfunction and foam cell formation have not been fully elucidated. The reference study (Tong et al., 2025) addresses whether SERCA2 dysfunction accelerates atherosclerosis by disrupting fatty acid metabolism and promoting foam cell formation, and evaluates whether targeting the downstream calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) pathway can mitigate these effects.

Key Innovation from the Reference Study

The central innovation of this work lies in uncovering a mechanistic axis—SERCA2 dysfunction activates calcineurin, which drives nuclear translocation of FoxO1, subsequently inducing FABP4 expression in macrophages. By pharmacologically inhibiting steps within this pathway, the study demonstrates reversal of aberrant lipid accumulation and foam cell formation, offering a targeted approach to correct maladaptive metabolic responses underlying atherosclerosis progression (Tong et al., 2025). Unlike prior studies focusing on single nodes in lipid metabolism or inflammation, this paper integrates upstream calcium handling (SERCA2), signal transduction (CaN/FoxO1), and fatty acid trafficking (FABP4), cementing a multi-layered mechanistic map relevant for translational research. The identification of FABP4 as both an effector and a tractable pharmacological target provides a direct bridge to intervention strategies using selective inhibitors such as BMS 309403.

Methods and Experimental Design Insights

To model SERCA2 dysfunction, the authors generated heterozygous knock-in (SKI) mice harboring a C674S mutation in the ATPase, mimicking pathological impairment. These animals, alongside wild-type littermates, were subjected to serum metabolomics, histological assessment of aortic lesions, and mechanistic studies in bone marrow-derived macrophages (BMDMs). Key methodological elements included:

• Comparative metabolomic profiling of serum from SKI and wild-type mice to reveal systemic metabolic disruptions.
• Histological quantification of atherosclerotic lesions in the aorta and aortic root, assessing plaque burden and foam cell prevalence.
• Ex vivo analysis of BMDMs for protein expression (Western blotting of CaN, FoxO1, FABP4), lipid uptake (fluorescence-based assays), and lipid accumulation (Oil Red O staining).
• Pharmacological inhibition of FoxO1 and FABP4 using small molecules, as well as genetic partial deficiency models, to dissect pathway contributions.

This integrative approach enabled the authors to link molecular signaling events with cellular phenotypes and systemic disease outcomes.

Core Findings and Why They Matter

The study's main findings are:

• SERCA2 dysfunction in SKI mice and their BMDMs leads to increased calcineurin activity, promoting FoxO1 nuclear localization and upregulation of FABP4 expression.
• Elevated FABP4 drives excessive fatty acid synthesis and cholesterol esterification in macrophages, promoting foam cell formation—a hallmark of early atherogenesis (Tong et al., 2025).
• Pharmacological inhibition of FoxO1 or FABP4, as well as partial genetic deficiency of FABP4, normalizes lipid metabolism and significantly reduces foam cell formation and atherosclerotic plaque development in the SKI model.

These findings establish the CaN/FoxO1/FABP4 axis as a critical mediator of SERCA2 dysfunction-induced atherogenesis. By demonstrating that selective FABP4 inhibition corrects downstream metabolic derangement, the study provides a mechanistic rationale for targeting FABP4 in atherosclerosis and related metabolic disorders.

Comparison with Existing Internal Articles

Multiple internal articles corroborate and contextualize these findings. For instance, "Inhibiting CaN/FoxO1/FABP4 Pathway Prevents Foam Cell Formation" and "Targeting CaN/FoxO1/FABP4 to Prevent SERCA2-Induced Atherosclerosis" both highlight how SERCA2 dysfunction promotes foam cell formation via this pathway and emphasize the therapeutic potential of FABP4 inhibition. "BMS 309403: Selective FABP4 Inhibitor for Atherosclerosis Research" further reviews the pharmacological properties and research applications of BMS 309403, underlining its value in probing the mechanistic roles of FABP4 in both inflammation and lipid handling. These articles, in concert with the reference study, reinforce the emerging paradigm that the CaN/FoxO1/FABP4 axis is not only mechanistically central but also pharmacologically actionable.

Limitations and Transferability

While the reference study offers compelling mechanistic and preclinical evidence, several limitations should be considered. The use of a specific SERCA2 mutation (C674S) in a murine model may not fully recapitulate the spectrum of SERCA2 dysfunction observed in human populations. Additionally, while in vitro and in vivo pharmacological inhibition of FABP4 yielded robust effects, the long-term safety, off-target consequences, and efficacy of such interventions in more complex or comorbid settings remain to be established. Finally, the pathway’s role in other cell types and in advanced or unstable plaques warrants further investigation. Despite these caveats, the highly conserved nature of the CaN/FoxO1/FABP4 axis and the translational relevance of foam cell biology suggest that the findings are likely to be broadly informative for cardiovascular and metabolic disease research.

Protocol Parameters

• Mouse model: Use heterozygous SERCA2 C674S knock-in mice to model calcium ATPase dysfunction in vivo.
• FABP4 inhibitor dosing: Literature reports typical in vitro concentrations for BMS 309403 ranging from 1–25 μM, with stock solutions prepared in DMSO or ethanol and stored at -20°C (product information).
• BMDM lipid loading: Incubate with modified LDL or fatty acid substrates for foam cell induction, followed by FABP4 inhibitor treatment.
• Histological analysis: Quantify lesion area and foam cell content in aorta and aortic root using Oil Red O and immunohistochemistry.
• Gene/protein expression: Assess CaN, FoxO1, and FABP4 in BMDMs via Western blotting and qPCR post-intervention.
• Serum metabolomics: Collect serum from experimental and control mice for targeted or untargeted metabolomic profiling.

Research Support Resources

Researchers aiming to investigate FABP4’s role in lipid metabolism, inflammation, or metabolic disease models can employ selective inhibitors such as BMS 309403 (SKU B7794) to replicate or extend findings from the reference study. BMS 309403 is a highly potent and selective FABP4 inhibitor, soluble in DMSO and suitable for both in vitro and in vivo applications. For detailed product handling and storage guidelines, reference the manufacturer's specifications. When designing experiments around the CaN/FoxO1/FABP4 axis, these resources provide a practical foundation for translational research on atherosclerosis and related metabolic disorders.